Clarity Pharmaceuticals Ltd
ASX:CU6
Intrinsic Value
The intrinsic value of one CU6 stock under the Base Case scenario is hidden AUD. Compared to the current market price of 3.61 AUD, Clarity Pharmaceuticals Ltd is hidden .
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Clarity Pharmaceuticals Ltd
CU6 looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether CU6 usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Clarity Pharmaceuticals Ltd.
Fundamental Analysis
Clarity's success hinges on its unproven copper-based radiopharmaceuticals; any unexpected safety issues or lack of efficacy data from ongoing clinical trials could significantly undermine investor confidence and jeopardize future funding.
Clarity’s copper-based radiopharmaceutical platform offers a differentiated approach with the potential for improved diagnostic accuracy and therapeutic effectiveness, putting it at the forefront of next-generation radiotherapy innovation.
Revenue & Expenses Breakdown
Clarity Pharmaceuticals Ltd
Balance Sheet Decomposition
Clarity Pharmaceuticals Ltd
| Current Assets | 100.6m |
| Cash & Short-Term Investments | 84.1m |
| Receivables | 10.1m |
| Other Current Assets | 6.4m |
| Non-Current Assets | 566k |
| PP&E | 552.5k |
| Other Non-Current Assets | 13.5k |
Free Cash Flow Analysis
Clarity Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Clarity Pharmaceuticals Ltd
|
Revenue
|
0
AUD
|
|
Operating Expenses
|
-69.1m
AUD
|
|
Operating Income
|
-69.1m
AUD
|
|
Other Expenses
|
4.8m
AUD
|
|
Net Income
|
-64.3m
AUD
|
CU6 Profitability Score
Profitability Due Diligence
Clarity Pharmaceuticals Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Clarity Pharmaceuticals Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
CU6 Solvency Score
Solvency Due Diligence
Clarity Pharmaceuticals Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Clarity Pharmaceuticals Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CU6 Price Targets Summary
Clarity Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CU6 is 7.55 AUD with a low forecast of 5.05 AUD and a high forecast of 9.66 AUD.
Dividends
Current shareholder yield for CU6 is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one CU6 stock under the Base Case scenario is hidden AUD.
Compared to the current market price of 3.61 AUD, Clarity Pharmaceuticals Ltd is hidden .